In case of Nexavar, another company is able to manufacture far more cheaply and that says something about Bayer. Either they are unable to manufacture cheaply or they are unwilling to price it cheaper.

Suppose that big pharma stops selling drugs in India. That wouldn't make much difference because the generic drug manufacturers would still make cheap copies of the drugs. The only downside would be that new drugs will take time to be introduced because of the time needed to reverse engineer the formulae and set up manufacturing capabilities.